between HLA-B*15:02 and CBZ-induced TEN/SJS in Han Chinese, [5] Thai, [2] and Korean populations. [3, 7] In subsequent studies, a strong association between CBZ-induced SCAR and HLA-B*15:02 was observed in several Han Chinese populations with high frequencies of this allele (94.11%), [5, [18] [19] [20] whereas interestingly, studies in some Asian populations, such as in Japanese [21, 22] and Europeans, [23, 24] did not find any association between HLA-B*15:02 and CBZ-induced cutaneous ADRs. However, the degree of the association between HLA-B*15:02 and CBZ-induced SCAR and its clinical significance remain uncertain in other populations.
The aim of the current study was to systematically review the association between the HLA-B*15:02 allele and CBZ-induced TEN/SJS in different populations. We also investigated the diagnostic performance and clinical utility of HLA-B*15:02 testing for the prevention of TEN/SJS in general populations who have either a high or low frequency of this allele.
MateRials and Methods
A comprehensive search of peer-reviewed articles indexed in the electronic databases of PubMed, EMBASE, and Ovid Medline was performed, and the reference lists of the retrieved articles were also reviewed to identify additional studies for inclusion.
The time frame for the electronic search was from January 2000 to December 2017 with no language restriction. Moreover, we reviewed the reference lists of several previously published reviews on HLA-B*15:02 testing. Search terms included "human leukocyte antigen," "HLA-B*15:02," "carbamazepine," "hypersensitivity," "screening," "sensitivity," "specificity," "predictive value," and "likelihood ratio."
When multiple articles for a single study had been published by the same teams or authors, we used the most relevant publication and supplemented it, if necessary, with data from the authors' other publications. Authors of studies were contacted when pertinent information was not available in the published version.
The quality of each included study was evaluated according to the Quality Assessment of Studies of Diagnostic Accuracy-2 (QUADAS-2). [25] Data were pooled by means of a random-effects model, and then, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive and negative likelihood ratios (LR+ and LR−), diagnostic odds ratios (DOR), summary receiver operating characteristic (SROC) curve, and 95% confidence intervals (CI) were calculated. [26] Heterogeneity across studies was assessed through the I 2 statistic. An I 2 statistic >50% was considered substantial heterogeneity. [26] If substantial heterogeneity existed, subgroup analyses would be conducted to explore the heterogeneity. [27] The primary analyses were based on population control studies. The primary outcomes were CBZ-induced TEN and SJS. The analyses were also performed separately on studies using different control groups (e.g., CBZ-treated control patients [CBZ-tolerant matched-control studies]).
Subgroup analyses by race/ethnicity were also performed to determine the robustness of the findings.
Results

Characteristics of the study populations
In the present study, we identified 201 articles from online databases, of which 126 irrelevant articles were excluded from the study. The remaining 75 articles were further assessed for eligibility, and 26 articles were finally included in the meta-analysis, consisting of a total of 4785 patients [Supplementary Table 1 ].
The quality of the included studies as assessed by the QUADAS-2 tool was generally high, with all studies meeting eight or more of the criteria. Figure 1 shows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram for studies retrieved through the electronic search and the selection processes for study inclusion.
Specifically, the studies included 373 TEN/SJS cases, 804 CBZ-tolerant matched-control subjects, and 3452 general population control subjects. The detailed characteristics of each study are presented in Supplementary Table 1 . Full-text articles excluded, with reasons (n = 44) -Review article ( 154 (0.8-895.24) . Figure 2 shows the HLA-B*15:02 allele frequencies of the general populations and their associations with CBZ-induced TEN/SJS in each of the ethnic groups of the included studies. Figure 2 shows the geographical distribution and frequencies of HLA-B*15:02 in different ethnic general populations with a >5% allele frequency. 
Analysis of population control and carbamazepine-tolerant matched-control studies
Statistical pooling of outcomes
Subgroup analysis
In the meta-analysis, it was revealed that there was considerable heterogeneity (I 2 > 50%) for all statistical measures except for the DOR, which had an I 2 = 51.6% [Supplementary 
discussion
Association of human leukocyte antigen-B*15:02 and carbamazepine-induced toxic epidermal necrolysis/ Stevens-Johnson syndrome across different populations
CBZ is widely used to treat epilepsy, bipolar disorder, trigeminal neuralgia, and chronic pain. [43] However, some patients develop adverse hypersensitivity reactions, ranging from mild skin rashes to life-threatening SCAR, including TEN and SJS. [14, 15] The identification of genetic markers that predispose individuals to the development of CBZ-induced TEN/SJS offers the possibility of those with such susceptibilities to avoid this drug. [36] However, there is no agreed-upon international guideline for HLA-B*15:02 screening before patients are treated with CBZ; US FDA has issued a black box warning for the physicians to test the allele before the initiation of carbamazepine. [11] In the present study, we found a strong association between HLA-B*15:02 and CBZ-induced TEN/SJS across different ethnic populations. [5, 21, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Given that CBZ-induced TEN/SJS has serious life-threatening consequences and has long-term sequelae after development, such as blindness and corneal opacity, and that there are available drug alternatives to CBZ, testing for HLA-B*15:02 before CBZ initiation may be valuable and justifiable to prevent TEN/SJS caused by CBZ.
In the present study, we investigated the diagnostic performance and clinical utility of HLA-B*15:02 testing for the prevention of TEN/SJS in general populations who have either a high (≥5%-10%) or low (<1%-5%) HLA-B*15:02 allelic frequency. Our results revealed that there was a strong relationship between the HLA-B*15:02 allele and CBZ-induced TEN/SJS in Han Chinese, [5, 15, 19, 28, 33] Thai, [2] and Korean. [3, 7] Overall, the pooled DOR for the relationship between the HLA-B [32] Another Indian study done in North Indian population observed an association between HLA-B*15:02 allele and CBZ-induced SJS/TEN. [45] A study done in Indian population in Malaysia, most of whom were of South Indian origin, also showed a strong association of HLA-B*15:02 allele and CBZ-induced SJS/TEN. [46] The increased risk of Severe Carbamazepine Hypersensitivity Syndrome in in the Chinese population stems from the higher frequency of the HLA-B*15:02 allele in this populations (allelic frequency ≥5% from the dbMHC database). [47] In the included studies herein, the overall pooled sensitivity and specificity of HLA-B*15:02 for detecting CBZ-induced TEN/SJS were 67% (95% CI = 63%-72%) and 98% (95% CI = 98%-99%), respectively [Supplementary In real-world clinical practice, the estimated low PPV (3%) [48] of HLA-B*15:02 testing is not of great concern because physicians would not intend to use CBZ in patients who are HLA-B*15:02 positive. Moreover, the aim of a screening test for drug hypersensitivity reactions is to have a high sensitivity and a high NPV. The optimal implementation of HLA-B*15:02 screening at this time is as an initial diagnostic test that offers significant arguments against CBZ-induced TEN/SJS if negative, as well as supportive information on the development of CBZ-induced TEN/SJS if positive, especially in those populations with a higher (≥5%) allele frequency. CBZ-induced TEN and SJS remain a life-threatening problem. In clinical practice, the incidence of SCAR in CBZ using patients was estimated to be 0.1%-0.4% in different ethnic populations [5, 21, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] including Han Chinese, [5] Thai, [2] and Korean populations. [3, 7] Carbamazepine is the leading cause of drug-induced toxic epidermal necrolysis/Stevens-Johnson syndrome in many countries
As previously mentioned, CBZ has been reported as one of the most common causes of SCAR, [1] [2] [3] 5] especially TEN/SJS, [5, 21, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] in many different countries. Through a review of the literature, we found that the leading cause of SCAR in many regions/countries, including Han Chinese, [5] Thai, [2] and Korean populations, [3, 7] has been reported to be CBZ. In contrast to previous studies, Huang et al. [49] found CBZ to be the most common single drug associated with cutaneous adverse drug reactions, followed by allopurinol and antibiotics. This observation is compatible to experiences in Taiwan where CBZ was the leading cause of TEN/SJS and SCAR in the last decade. [50] In a previous study, data from surveillance networks in France, Germany, Italy, and Portugal from 1989 to 1993 revealed that the use of antibacterial sulfonamides, anticonvulsant agents (CBZ), nonsteroidal anti-inflammatory drugs (oxicam), and allopurinol was associated with a large increase in the risk of TEN and SJS. [14] 
Genetic and clinical factors associated with c a r b a m a z e p i n e -i n d u c e d t o x i c e p i d e r m a l necrolysis/Stevens-Johnson syndrome
To date, the pathogenesis of TEN and SJS is still not completely understood. The proteins encoded by the HLA genes located on the major histocompatibility complex (MHC) region of the human chromosome 6p21.3 play a central role in immune reactions by presenting antigens to T-cell receptors. [51] The strong associations between HLA-B*15:02 and CBZ-induced TEN/SJS suggest that genetic predisposition plays an important role in the pathogenesis of TEN/SJS. It is not clear why only 3% [48] of HLA-B*15:02-positive patients developed SCAR after taking CBZ, which suggests that other factors may also be involved in mediating the increased risk. [12] Although the precise mechanisms involved in SCAR development and TEN/SJS are still unclear, several different factors have been postulated in their pathogenesis, [52, 53] which have mainly included those related to cell-mediated immunity directed to CBZ, in addition to viruses, genetic factors, and metabolic pathways. [5, 21, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Cutaneous drug reactions may be caused by several different mechanisms. [14] TEN and SJS are characterized by massive keratinocyte apoptosis. [14] Wei et al. suggested that the endogenous peptide-loaded HLA-B*15:02 molecule presented CBZ to cytotoxic T lymphocytes (CTLs) without the involvement of intracellular drug metabolism or antigen processing. The HLA-B*15:02/ peptide/β2-microglobulin protein complex showed binding affinity toward chemicals sharing 5-carboxamide on the tricyclic ring, as with CBZ. However, modifications of the ring structure of CBZ altered HLA-B*15:02 binding and CTL response. In addition to HLA-B*15:02, other HLA-B*75 family members could also present CBZ to activate CTLs, whereas members of the HLA-B*62 and HLA-B*72 families could not. Three residues (Asn63, Ile95, and Leu156) in the peptide-binding groove of HLA-B*15:02 were involved in CBZ presentation and CTL activation. In particular, Asn63 shared by members of the B*75 family was the key residue. Computer simulations revealed a preferred molecular conformation of the 5-carboxamide group of CBZ and the side chain of Arg62 on the B pocket of HLA-B*15:02. [54] In addition, other genetic and clinical factors may influence a patient's risk of CBZ-induced adverse reactions. However, given our current knowledge regarding CBZ-induced TEN/SJS, HLA-B*15:02 testing is beneficial in clinical practice for patients who are about to initiate CBZ, especially for those from ethnic backgrounds with a higher (≥5%) risk allele frequency [ Figure 4 ]. Particularly, these patients should be advised about the availability of such a test so that they can choose to be genotyped if they have concerns about TEN/SJS, which can be potentially life threatening. Moreover, it should be noted that the risk of developing CBZ-induced TEN/SJS is the highest in the first 3 months of drug treatment, [55] whereas the risk of TEN/SJS is very low for patients who have already been treated with CBZ for more than 3 months and thus generally do not require testing. Therefore, there is an urgency to better understand the mechanisms and factors that predispose individuals to CBZ-induced SCAR and TEN/SJS. The higher rates of TEN/SJS in Asians are likely related to the high frequency of the HLA-B*15:02 allele in Asian populations compared to that in other ethnicities. Comprehensive lists of HLA-B*15:02 frequencies by ethnicity are available elsewhere and are summarized as follows: Australia, 15.6%; Cape York, 15%; Europe, 5.8%; Croatian, 7%; Cuban, 4.3%; North America, 7.5%; North Africa, 3.3%; Brazilian, 7.6%; Han Chinese, 11.7%; New Delhi, 3%; Sub-Saharan Africa, 14.6%; Ugandan, 13.1%; and Zambian, 13.6% [ Figure 2 ]. [47] It is interesting to note that the strength of genetic associations that have been found directly relates to the prevalence of the susceptibility allele in the different ethnic populations with consistent results reported from Southeast and South Asia, Thailand, and Korea where the frequencies of the risk alleles are high (≥5%). Given that HLA-B*15:02 testing has a very high specificity and high NPV, it is apparent that over 99% of CBZ-induced TEN/SJS is preventable through pretreatment screening in those populations with a reasonably high carrier rate (i.e., high-risk subpopulations) of the HLA-B*15:02 allele.
Our systematic meta-analysis focused only on the relationship between the HLA-B*15:02 allele and CBZ-induced SJS and TEN. Other genes that may be associated with SJS and TEN (such as HLA-A*31:01) were excluded from our study. [56] In summary, there are no compelling data to show that two HLA alleles predispose to different forms of CBZ hypersensitivity. One of these tests, HLA-B*15:02, is already used in Asian countries before the initiation of CBZ therapy. HLA-A*31:01 has been more recently identified, and whether the test is adopted by clinicians and the drug label changed by regulators are unclear at present. However, given that the test characteristics are comparable to those for HLA-B*1502, we are in favor of a label change. Additional work -specifically, further studies to determine the causal pathways that may help in improving the test characteristics -is needed. Different ethnic populations should also be studied for the association between CBZ hypersensitivity and HLA allele frequencies. Moreover, whether these tests are applicable for other phenotypes, for example, liver injury; whether HLA-A*31:01 also predisposes to hypersensitivity reactions with other antiepileptic drugs; and whether testing is cost-effective and acceptable among clinicians and patients still needs to be determined.
conclusions
We found a strong relationship between HLA-B*15:02 and CBZ-induced SJS and TEN in Han Chinese, Thai, and Malaysian populations. The recognition of HLA-B allele status before initiation of the drug may be beneficial to some groups of patients. Such information will assist physicians in determining the optimal drug therapy.
What is known about this topic
The clinical features of CBZ hypersensitivity suggest an immune-mediated etiology, and the discovery of drug-specific T-cells in hypersensitive individuals is consistent with this hypothesis. HLAs play a central role in the immune response to antigens, and it has been hypothesized that specific HLA molecules may present a drug or its metabolites to specific T-cells, which subsequently triggers an immune response. This has been borne out by studies that have shown strong associations with two HLA alleles, particularly HLA-B*15:02, which was first reported in Han Chinese patients, and HLA-A*31:01, which has been reported in Japanese and Caucasian populations.
What this study adds
We found a strong relationship between HLA-B*15:02 and CBZ-induced SJS and TEN in Han Chinese, Thai, and Malaysian populations. Screening of HLA-B*15:02 may help patients to prevent the occurrence of CBZ-induced TEN/ SJS, especially in populations with a higher (≥5%) risk allele frequency.
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